Bristol-Myers Squibb Company (NYSE: BMY) reported second-quarter adjusted earnings of $2.04 per share, surpassing the Wall Street estimate of $1.59, and raised its full-year fiscal 2026 guidance on robust performance from its growth portfolio. The pharmaceutical giant posted quarterly revenue of $12.973 billion, a 6% increase that exceeded the consensus estimate of $11.745 billion, driven by double-digit growth in key products such as Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag.

Christopher Boerner, board chair and CEO of Bristol-Myers Squibb, attributed the positive results to consistent execution and a differentiated pipeline designed to generate long-term value. Consequently, the company increased its fiscal 2026 adjusted earnings guidance from $6.05-$6.35 per share to $6.75-$7 per share, beating the consensus of $6.34 per share. Additionally, Bristol-Myers Squibb raised its fiscal 2026 sales guidance from $46 billion-$47.50 billion to $49 billion-$50 billion, compared to the consensus of $47.472 billion.

Portfolio Performance Breakdown

The company’s Growth Portfolio generated revenues of $7.6 billion, representing a 15% increase (14% on a constant currency basis). This segment was primarily propelled by newer therapies including Opdivo Qvantig and Reblozyl. In contrast, the Legacy Portfolio saw revenues decline by 4% (5% on constant currency) to $5.4 billion. While demand for Eliquis increased significantly, this gain was offset by expected generic impacts across other legacy products.

Outlook and Dividend Implications

Bristol-Myers Squibb expects global Eliquis revenue to grow by 20% to 25% in fiscal 2026. The updated guidance assumes continued strength in the Growth Portfolio alongside a projected 4%-6% decline in the Legacy Portfolio. Shares of Bristol-Myers Squibb rose 2.38% to close at $64.56 following the announcement.

For income-focused investors, the stock’s annual dividend yield stands at approximately 3.96%, with a quarterly payout of $0.63 per share ($2.52 annually). To generate a monthly dividend income of $500 ($6,000 annually), an investor would need to hold approximately 2,381 shares, representing an investment of roughly $151,432 at current prices. A more conservative target of $100 monthly ($1,200 annually) requires holding 476 shares, or about $30,274 worth of stock.

What the Numbers Show

The divergence between the Growth and Legacy portfolios highlights Bristol-Myers Squibb’s successful transition toward newer, higher-margin therapies. While the Legacy Portfolio faces headwinds from generic competition, the 15% surge in Growth Portfolio revenue demonstrates the commercial traction of recent innovations. The significant raise in full-year guidance suggests management confidence in sustaining this momentum, particularly given the projected 20%-25% growth for Eliquis, which remains a critical cash flow generator despite broader legacy declines.

Bristol Myers Squibb Co is significantly upgrading its computational capabilities by deploying an NVIDIA Corp DGX SuperPOD equipped with DGX Vera Rubin NVL72 systems. The strategic deployment establishes the most robust and energy-efficient single-owned artificial intelligence infrastructure currently operating within the life sciences sector. The expanded Vera Rubin infrastructure will deliver up to ten times greater performance per megawatt than its predecessor, allowing the company to pursue larger and more sophisticated AI workloads without a proportional increase in energy consumption.

The investment builds on nearly three years of collaboration that began when Bristol Myers Squibb first deployed NVIDIA DGX SuperPOD infrastructure. This expansion extends a relationship that matches the growing scope of the company's AI-driven scientific programs across oncology, hematology, cardiovascular, immunology, and neuroscience. The move also builds on the company’s broader AI strategy, including a strategic agreement with Anthropic signed in May to deploy AI across its operations and give more than 30,000 employees access to institutional knowledge.

Strategic Impact on Operations

Bristol Myers Squibb's investment in AI-powered research has already begun to alter how the company discovers and develops medicines. AI agents that automate target identification and validation save scientists weeks of manual work, allowing researchers to focus on hypothesis testing and high-value scientific decisions. Through the company's "Predict First" approach, AI-generated predictions inform experimental design before work begins at the bench. Bristol Myers said AI now supports the design of every small-molecule drug program and most large-molecule development projects.

The enhanced computing capacity will support the development of next-generation foundation models trained on decades of proprietary research data. It also draws on domain-specific capabilities from BioNeMo, NVIDIA's platform for biological AI. The announcement follows another AI-focused partnership unveiled in May with Tempus AI Inc., where the companies agreed to use AI and multimodal real-world data to improve clinical trial design across five initial oncology and neuroscience development programs.

Executive Perspectives

"BMS has made a deliberate bet on AI, and we are beginning to see it pay off in our pipeline and operations," said Greg Meyers, Chief Digital and Technology Officer at Bristol Myers Squibb. "We're committed to translating AI into real outcomes for patients which requires infrastructure built to match that ambition."

"Drug discovery is a sequence of decisions made under uncertainty, and better decisions come from better evidence, faster," said Robert Plenge, Executive Vice President and Chief Research Officer at Bristol Myers Squibb. "This infrastructure lets us learn from every experiment and every clinical readout to sharpen the next hypothesis."